PTC Therapeutics won a bankruptcy auction for Sangamo’s Fabry disease gene therapy candidate, taking the program forward with an agreement framed as a near-BLA path. The deal structure combines upfront cash with milestone payments tied to regulatory approvals, highlighting how asset consolidation is accelerating access to late-stage gene therapy candidates. Eli Lilly also acquired technology rights from Sangamo in a separate component of the auction process. The transaction set underscores the market’s focus on late clinical readiness and regulatory momentum after Sangamo’s Chapter 11 filing.